53.36
前日終値:
$55.04
開ける:
$54.1
24時間の取引高:
451.35K
Relative Volume:
0.68
時価総額:
$1.58B
収益:
$232.39M
当期純損益:
$-26.79M
株価収益率:
-49.39
EPS:
-1.0804
ネットキャッシュフロー:
$4.41M
1週間 パフォーマンス:
-1.46%
1か月 パフォーマンス:
-20.95%
6か月 パフォーマンス:
+12.55%
1年 パフォーマンス:
+117.35%
Anaptysbio Inc Stock (ANAB) Company Profile
名前
Anaptysbio Inc
セクター
電話
858-362-6295
住所
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
ANAB
Anaptysbio Inc
|
53.36 | 1.59B | 232.39M | -26.79M | 4.41M | -1.0804 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-10-13 | 開始されました | Barclays | Overweight |
| 2025-06-04 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | 開始されました | Wolfe Research | Outperform |
| 2024-12-11 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-07-22 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-19 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-04-16 | 開始されました | Leerink Partners | Outperform |
| 2024-04-11 | 開始されました | Wells Fargo | Overweight |
| 2024-03-12 | アップグレード | Wedbush | Neutral → Outperform |
| 2024-02-26 | 開始されました | BTIG Research | Buy |
| 2024-02-21 | 開始されました | Stifel | Buy |
| 2024-02-16 | 開始されました | Piper Sandler | Overweight |
| 2023-05-22 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-05-18 | 開始されました | TD Cowen | Outperform |
| 2023-01-06 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-09-19 | 再開されました | H.C. Wainwright | Buy |
| 2022-09-13 | ダウングレード | Truist | Buy → Hold |
| 2022-09-01 | 開始されました | Raymond James | Outperform |
| 2022-03-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-06-22 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-21 | 開始されました | UBS | Neutral |
| 2021-03-16 | アップグレード | Truist | Hold → Buy |
| 2021-03-09 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-03-08 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2021-02-11 | アップグレード | JP Morgan | Underweight → Overweight |
| 2020-10-27 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-10-14 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-11-08 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2019-11-08 | ダウングレード | Jefferies | Buy → Hold |
| 2019-11-08 | ダウングレード | SunTrust | Buy → Hold |
| 2019-11-08 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-06-21 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | ダウングレード | Stifel | Buy → Hold |
| 2018-12-20 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-21 | 開始されました | JP Morgan | Overweight |
| 2018-07-19 | 開始されました | Credit Suisse | Outperform |
| 2018-04-04 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | 繰り返されました | Stifel | Buy |
| 2018-03-06 | 繰り返されました | Stifel | Buy |
| 2018-02-15 | 繰り返されました | SunTrust | Buy |
| 2018-01-23 | 繰り返されました | Credit Suisse | Outperform |
| 2017-11-15 | 開始されました | SunTrust | Buy |
| 2017-11-09 | 開始されました | Jefferies | Buy |
| 2017-10-11 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Anaptysbio Inc (ANAB) 最新ニュース
Eversept Partners LP Decreases Stock Position in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio Inc (ANAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AnaptysBio Inc (ANAB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ANAB|AnaptysBio Inc|Price:53.775|Chg%:+0.165 - TradingKey
AnaptysBio Inc (ANAB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
First Light Asset Management LLC Decreases Stock Holdings in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio Inc (ANAB) Cash Flow - TradingKey
AnaptysBio Inc (ANAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AnaptysBio Inc (ANAB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ANAB|AnaptysBio Inc|Price:53.486|Chg%:-0.124 - TradingKey
ANAB|AnaptysBio Inc|Price:54.150|Chg%:-0.760 - TradingKey
TradingKey - TradingKey
AnaptysBio, Inc. $ANAB Shares Sold by Granahan Investment Management LLC - MarketBeat
AnaptysBio Inc (ANAB) Income Statement - TradingKey
Anaptysbio, Inc Net Worth (2026) - GuruFocus
Affinity Asset Advisors LLC Boosts Position in AnaptysBio, Inc. $ANAB - MarketBeat
Hsbc Holdings PLC Buys New Shares in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio Inc (ANAB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AnaptysBio (NASDAQ:ANAB) Trading Up 5.6%Here's What Happened - MarketBeat
Barclays Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75 - Moomoo
AnaptysBio Declines 2.14% as Shares Test Key Support ZoneVolatility Term Structure - dars.gov.et
AnaptysBio Q1 2026 Earnings: Significant EPS Miss as Pipeline Costs Weigh on ResultsEarnings Call Q&A - dars.gov.et
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), UnitedHealth (UNH) and AnaptysBio (ANAB) - The Globe and Mail
H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $95 - Moomoo
AnaptysBio (NASDAQ:ANAB) Shares Down 6.2%Here's Why - MarketBeat
AnaptysBio, Inc.'s Equity Buyback announced on March 24, 2025 has expired with 3,444,079 shares, representing 11.5% for $68.63 million. - marketscreener.com
AnaptysBio (NASDAQ:ANAB) Trading 5.3% HigherShould You Buy? - MarketBeat
Is AnaptysBio (ANAB) Undervalued Following Its Jemperli Royalty Appeal And GSK Trial? - Sahm
AnaptysBio (NASDAQ:ANAB) Shares Gap DownWhat's Next? - MarketBeat
Significant Decline for AnaptysBio (ANAB) as Shares Drop Over 10% - GuruFocus
Barclays Keeps Their Buy Rating on AnaptysBio (ANAB) - The Globe and Mail
AnaptysBio (NASDAQ:ANAB) Shares Down 7%Time to Sell? - MarketBeat
What Makes AnaptysBio (ANAB) an Investment Bet? - Yahoo Finance
Laughing Water Capital Q2 2026 Letter - Seeking Alpha
TD Cowen Remains a Buy on AnaptysBio (ANAB) - The Globe and Mail
Form 144 ANAPTYSBIO For: 13 July By Investing.com - Investing.com Australia
AnaptysBio (NASDAQ: ANAB) insider files to sell 10,694 shares after option exercise - Stock Titan
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75 - Moomoo
AnaptysBio (ANAB) Holds Near Support as Biotech Sentiment Remains CautiousCup and Handle - dars.gov.et
Is AnaptysBio (ANAB) outperforming other medical stocks this year? - MSN
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Should AnaptysBio’s (ANAB) Russell Index Removal Prompt a Rethink of Its Liquidity and Investor Base? - simplywall.st
(ANAB) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Analysts Are Bullish on Top Healthcare Stocks: MindWalk Holdings (HYFT), AnaptysBio (ANAB) - The Globe and Mail
UBS Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $76 - Moomoo
AnaptysBio, Inc. Financial Disclosures & Filings - TradingView
CapForce IBD 50 ETF's AnaptysBio Inc(ANAB) Holding History - GuruFocus
Form 144 ANAPTYSBIO For: 30 June By Investing.com - Investing.com Nigeria
[144] ANAPTYSBIO, INC SEC Filing - Stock Titan
AnaptysBio Is Maintained at Buy by UBS - Moomoo
Is AnaptysBio’s (ANAB) Index Exit and Office Sublease Quietly Reframing Its Strategic Focus? - simplywall.st
Anaptysbio Inc (ANAB) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):